The product, Atorvastatin Magnesium, has been launched by four of Spain’s largest generic pharmaceutical companies. Actavis recently announced that its third-party sales division, Medis, has delivered around 30 million tablets of Atorvastatin to its clients in Spain. This is the first generic version of the blockbuster molecule to reach the Spanish market and distribution to Spanish pharmacies has already commenced. Read the full story

Iceland-based generic drugs company Actavis announced this week it has sold a product portfolio of seven established brands on the Polish market to Glenmark Pharmaceuticals, an Indian company hoping to build its presence in eastern and central Europe.

The sale took effect on 1st July, but neither company revealed the amount of money paid. The portfolio of seven products includes the antidepressant Cital and Lamotrix, which is used to treat epilepsy.

Actavis undertook the deal in collaboration with Biovena, its Polish subsidiary, and did so because of “Ongoing integration”, company sources said.

Actavis has acquired more than 20 companies in recent years, which it is now integrating into its existing product portfolio.

The company says this latest deal is intended to streamline Actavis’s extensive activities in Poland, in addition to bringing in an undisclosed lump sum from the sale itself.

Generic drug manufacturer Actavis in Serbia has been awarded a number of certificates for product quality, the environment and occupational health and safety.

The Iceland-based generic drug manufacturer received the ISO and OHSAS awards at a recent presentation ceremony in Belgrade. The certificates were issued by SGS, an international inspection, testing and certification company.

Actavis received certificates for the international standards ISO 9001:2000 (quality) and ISO 14001 (environment), as well as OHSAS 18001 (occupational health and safety).

“Great teamwork and the efforts of all our employees have brought our company to the highest European quality, environmental and health and safety standards,” said Goran Stojilkovic, Managing Director of Actavis in Serbia. “We are proud of our company’s commitment to developing environmental awareness in the local community,” he added.

Actavis is a leading generic drugs manufacturer which specialises in the development, production and sale of generic pharmaceuticals. Based in Iceland, the company has operations in 40 countries and 11,000 employees.

For more information on Actavis visit www.actavis.com